Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 6, 2018 4:01 PM ESTSAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the third quarter ended September 30, 2018 and provided an update on the company's recent achievements and upcoming milestones.
"In the third quarter, we continued to see exciting progress in the clinical development of AT132," stated Matthew R. Patterson, Chairman and Chief Executive Officer. "We recently presented new ASPIRO data at the 23rd International Annual Congress of the... More
